Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial.

Although a trend was observed suggesting gene signatures profiling score was higher in responders versus non-responders (per RECIST), particularly with the T-cell effector signature, these associations did not reach statistical significance ( Figure S2 ).

also in 111,027 other papers